Chai S, Zhang R, Zhang Y, Carr RD, Zheng Y, Rajpathak S, Ji L (2022) <br />Effect of dipeptidyl peptidase-4 inhibitors on postprandial glucagon level in patients with type 2 diabetes mellitus: A systemic review and meta-analysis<br /><i>Front Endocrinol (Lausanne)</i> <b>13</b>: 994944<br /><br />Berger JP, SinhaRoy R, Pocai A, Kelly TM, Scapin G, Gao YD, Pryor KAD, Wu JK, Eiermann GJ, Xu SS, Zhang X, Tatosian DA, Weber AE, Thornberry NA, Carr RD (2018) <br />A comparative study of the binding properties, dipeptidyl peptidase-4 (DPP-4) inhibitory activity and glucose-lowering efficacy of the DPP-4 inhibitors alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin in mice<br /><i>Endocrinol Diabetes Metab</i> <b>1</b>: e00002<br /><br />Carr RD, Larsen MO, Jelic K, Lindgren O, Vikman J, Holst JJ, Deacon CF, Ahren B (2010) <br />Secretion and dipeptidyl peptidase-4-mediated metabolism of incretin hormones after a mixed meal or glucose ingestion in obese compared to lean, nondiabetic men<br /><i>J Clinical Endocrinology Metab</i> <b>95</b>: 872<br /><br />Deacon CF, Carr RD, Holst JJ (2008) <br />DPP-4 inhibitor therapy: new directions in the treatment of type 2 diabetes<br /><i>Front Biosci</i> <b>13</b>: 1780<br /><br />Ryskjaer J, Deacon CF, Carr RD, Krarup T, Madsbad S, Holst J, Vilsboll T (2006) <br />Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake<br /><i>European Journal of Endocrinology</i> <b>155</b>: 485<br /><br />Plamboeck A, Holst JJ, Carr RD, Deacon CF (2005) <br />Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig<br /><i>Diabetologia</i> <b>48</b>: 1882<br /><br />